Four Parties Join Hands to Create the Future | The 4th "Four-Party Co-construction Seminar" Successfully Held

On July 24, the "4th 'High-Quality Party Building Promotes High-Quality Development' Four-Party Co-construction Seminar", co-hosted by Leadingpharm Pharmaceutical, Shanghai Haoyuan, College of Chemistry of Beijing Normal University, and College of Chemistry and Chemical Engineering of Lanzhou University, was successfully held at Lanzhou University.
 

More than 30 people attended the event, including Mr. Tao Xinhua, Chairman of Leadingpharm; Mr. Zhang Ronghuo, Vice President; Ms. Dong Ying, Vice President; Mr. Yang Huijun, Senior Training Manager; Ms. Li Mengqi, Medical Manager; Mr. Wang Wei, Vice President of Lanzhou University and Director of the State Key Laboratory of Applied Organic Chemistry; Mr. Du Shengyi, Secretary of the Party Committee of College of Chemistry and Chemical Engineering of Lanzhou University; Mr. Liang Yongmin, Dean; Ms. Yang Zhao, Secretary of the Party Committee of College of Chemistry of Beijing Normal University; and Mr. Yang Shaobo, Senior Vice President of Shanghai Haoyuan Pharmaceutical Co., Ltd.

Participants shared and reported on the research progress in the field of pharmaceutical R&D, and conducted in-depth exchanges and discussions on new mechanisms and models of industry-university-research cooperation, as well as technological innovation and achievement transformation. The event was hosted by Professor Lu Zhonglin from College of Chemistry of Beijing Normal University and Mr. Yang Shaobo, Senior Vice President of Shanghai Haoyuan Pharmaceutical Co., Ltd.

Ms. Li Mengqi, Medical Manager of Leadingpharm Pharmaceutical, pointed out that drug R&D is currently facing difficulties such as unbalanced investment-return ratio, long time consumption, and high failure rate. Based on Leadingpharm's long-term accumulated rich experience in clinical research, she introduced the pitfalls to avoid in the process of drug transformation and Leadingpharm Pharmaceutical's service philosophy of "being a full-process partner in new drug creation", aiming to help universities transform and implement innovative achievements.
 

Professor Cui Mengchao from Beijing Normal University shared the research progress in radiopharmaceuticals, focusing on the R&D progress of radiopharmaceuticals for detecting β-amyloid protein in Alzheimer's disease and the research results of fluorescent probe drugs for detecting prostate cancer.
 

Professor Guo Jing from Beijing Normal University introduced the technical composition, relevant principles, and application results of "molecular recognition based on high-resolution scanning probe technology".
 

Professor Wang Xiaolei from Lanzhou University introduced the background, principles, and synthesis of glycolipid agonists, and demonstrated the research results and application of glycolipid adjuvants.
 

Professor Chen Xiaoming from Lanzhou University presented the synthetic route to the schinortriterpenoid Rubriflordilactone A and shared the difficulties and challenges he encountered during the research.
 

Mr. Du Shengyi, Secretary of the Party Committee of College of Chemistry and Chemical Engineering of Lanzhou University, pointed out that universities have the advantage of solving scientific problems, while enterprises have the advantage of product transformation and application. One of the difficulties in the field of pharmaceutical R&D is the lack of in-depth docking, communication, and cooperation between industry, university, and research institutions. We should remember General Secretary Xi Jinping's instructions, adhere to writing papers on the land of the motherland, apply scientific and technological achievements in the great cause of modernization, and deeply promote school-enterprise exchanges and cooperation through the four-party co-construction seminar, so as to "move scientific research achievements from bookshelves to shelves" and actively serve the national strategy.

Ms. Yang Zhao, Secretary of the Party Committee of College of Chemistry of Beijing Normal University, stated that Beijing Normal University has done a lot of work in recent years in terms of excellent teacher training, professional setting adjustment, and joint student training. Universities cannot engage in innovation behind closed doors or alone; they must organically integrate with various innovation resources and enhance their innovation capabilities through collaborative innovation to jointly promote progress in the field of pharmaceutical R&D.

Mr. Liang Yongmin, Dean of College of Chemistry and Chemical Engineering of Lanzhou University, said that taking this conference and forum as an opportunity, they will further consolidate and expand cooperation results, deepen exchanges and cooperation with all parties, integrate resources, form synergy, strengthen measures, and innovate methods, striving to build a new pattern of four-party co-construction and a new model of multi-party school-enterprise cooperation featuring resource sharing, complementary advantages, mutual promotion, and common progress.

Mr. Tao Xinhua, Chairman of Leadingpharm, summarized that the four-party co-construction forum is an innovative model of school-enterprise exchanges and cooperation. School-enterprise collaboration has ensured the sustainable development of the pharmaceutical R&D and application field in terms of academic depth and financial support. We need to further explore and clarify the core issue of "how to give play to the leading role of Party building and transform it into a strong driving force for scientific research innovation and cross-field cooperation", so as to jointly promote the prosperity and progress of the entire industry.

-END-